Wenyi Tang1, James Yeh2, Jian Chen1, Mao Liu1, Jianting Ke3, Guangyi Tan1, Xiufang Lin1, Wei Wu1. 1. Department of Cardiology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519099, China. 2. National Heart and Lung Institute, Imperial College London, London, UK. 3. Department of Nephrology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China.
Abstract
BACKGROUND: The potential benefits and risks of extended thienopyridine therapy beyond 12 months after drug-eluting stent (DES) implantation remain unclear. METHODS: Randomized controlled trials (RCTs) were searched in PubMed, EMBASE, the Cochrane Library and China National Knowledge Infrastructure databases. The adverse clinical endpoints were compared between 12 months group (aspirin alone) and >12 months group (additional thienopyridine plus aspirin after 12-month dual antiplatelet therapy). Odds ratios (ORs) with 95% confidence intervals (95% CIs) were used as summary statistics. A random-effect model was used in the meta-analysis process. RESULTS: Finally, three RCTs incorporating 16,265 participants were included in this meta-analysis. The results indicated that the incidences of myocardial infarction (1.55% vs. 2.90%; OR =0.58; 95% CI, 0.40-0.84; P=0.004) and stent thrombosis (0.32% vs. 0.98%; OR =0.35; 95% CI, 0.20-0.62; P<0.001) in the >12 months group were significantly lower than the 12 months group. However, compared to the 12 months group, the extended thienopyridine therapy markedly increased the risk of bleeding events (2.09% vs. 1.28%; OR =1.64; 95% CI, 1.23-2.17; P<0.001). The risks of stroke (0.78% vs. 0.84%; P=0.67) and cardiac death (0.94% vs. 0.89%; P=0.61) were similar between the two groups. CONCLUSIONS: The synthesis of available evidence indicates that a regimen of extended thienopyridine therapy beyond 12 months may significantly reduce the risks of myocardial infarction and stent thrombosis but increase the risk of bleeding events in the patients who have received DESs implantation.
BACKGROUND: The potential benefits and risks of extended thienopyridine therapy beyond 12 months after drug-eluting stent (DES) implantation remain unclear. METHODS: Randomized controlled trials (RCTs) were searched in PubMed, EMBASE, the Cochrane Library and China National Knowledge Infrastructure databases. The adverse clinical endpoints were compared between 12 months group (aspirin alone) and >12 months group (additional thienopyridine plus aspirin after 12-month dual antiplatelet therapy). Odds ratios (ORs) with 95% confidence intervals (95% CIs) were used as summary statistics. A random-effect model was used in the meta-analysis process. RESULTS: Finally, three RCTs incorporating 16,265 participants were included in this meta-analysis. The results indicated that the incidences of myocardial infarction (1.55% vs. 2.90%; OR =0.58; 95% CI, 0.40-0.84; P=0.004) and stent thrombosis (0.32% vs. 0.98%; OR =0.35; 95% CI, 0.20-0.62; P<0.001) in the >12 months group were significantly lower than the 12 months group. However, compared to the 12 months group, the extended thienopyridine therapy markedly increased the risk of bleeding events (2.09% vs. 1.28%; OR =1.64; 95% CI, 1.23-2.17; P<0.001). The risks of stroke (0.78% vs. 0.84%; P=0.67) and cardiac death (0.94% vs. 0.89%; P=0.61) were similar between the two groups. CONCLUSIONS: The synthesis of available evidence indicates that a regimen of extended thienopyridine therapy beyond 12 months may significantly reduce the risks of myocardial infarction and stent thrombosis but increase the risk of bleeding events in the patients who have received DESs implantation.
Authors: Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting Journal: Catheter Cardiovasc Interv Date: 2012-02-15 Impact factor: 2.692
Authors: Tullio Palmerini; Ajay J Kirtane; Patrick W Serruys; Pieter C Smits; Elvin Kedhi; Dean Kereiakes; Diego Sangiorgi; Letizia Bacchi Reggiani; Christoph Kaiser; Hyo-Soo Kim; Antoinette De Waha; Flavio Ribichini; Gregg W Stone Journal: Circ Cardiovasc Interv Date: 2012-06-05 Impact factor: 6.546
Authors: Caroline Franck; Mark J Eisenberg; Tara Dourian; Sonia M Grandi; Kristian B Filion Journal: Int J Cardiol Date: 2014-11-05 Impact factor: 4.164
Authors: Philippe Kolh; Stephan Windecker; Fernando Alfonso; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart J Head; Peter Jüni; A Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Josef Neumann; Dimitrios J Richter; Patrick Schauerte; Miguel Sousa Uva; Giulio G Stefanini; David Paul Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Çetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Miguel Sousa Uva; Stephan Achenbach; John Pepper; Anelechi Anyanwu; Lina Badimon; Johann Bauersachs; Andreas Baumbach; Farzin Beygui; Nikolaos Bonaros; Marco De Carlo; Christi Deaton; Dobromir Dobrev; Joel Dunning; Eric Eeckhout; Stephan Gielen; David Hasdai; Paulus Kirchhof; Heyman Luckraz; Heiko Mahrholdt; Gilles Montalescot; Domenico Paparella; Ardawan J Rastan; Marcelo Sanmartin; Paul Sergeant; Sigmund Silber; Juan Tamargo; Jurrien ten Berg; Holger Thiele; Robert-Jan van Geuns; Hans-Otto Wagner; Sven Wassmann; Olaf Wendler; Jose Luis Zamorano Journal: Eur J Cardiothorac Surg Date: 2014-08-29 Impact factor: 4.191
Authors: Kirk N Garratt; W Douglas Weaver; Ronald G Jenkins; Thomas K Pow; Laura Mauri; Dean J Kereiakes; Kenneth J Winters; Thomas Christen; Dominic J Allocco; David P Lee Journal: Circulation Date: 2014-11-16 Impact factor: 29.690
Authors: Sammy Elmariah; Laura Mauri; Gheorghe Doros; Benjamin Z Galper; Kelly E O'Neill; Philippe Gabriel Steg; Dean J Kereiakes; Robert W Yeh Journal: Lancet Date: 2014-11-16 Impact factor: 79.321